Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (271)	4/13/2005 1:13:42 AM
From: zeta1961	Respond to of 802

Thanks Ian..we'll stay tuned..these analysts are hostile about INGN/to INGN..feelings with Nance the CEO are mutual..no love lost..he blew them off and went to Europe for financing last year, he's got the NCI paying for 25+ clinical trials..at this point, Nance has given the proverbial finger to Wall Street and will speak to them at the time of his choosing..when he gets a product approved.. I can say that INGN is not reckless..they know the burden/responsibility/prize is resting with them regarding a gene therapy product since they are furthest along in development..I trust their choices made thus far..the noise about 'subset analysis', retrospective..yadda, yadda..is just that..noise...........there are scientists who've spent the bulk of their careers on this project..placed themselves on the the line and the fringe from their peers....I trust them more than any analyst.. That said, I do think Advexin should not get accelerated approval but go through the difficult hurdles at the FDA..unless there's compelling data in that subset.. Never a dull moment in bio! Zeta Zeta